1h Free Analyst Time
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Prolyl 4 hydroxylases (P4H) are iron- and 2-oxoglutamate-dependent dioxygenase enzymes and hypoxia-inducible transcription factor (HIF)-P4Hs play a critical role in the regulating oxygen homeostasis in the local tissues as well in the systemic circulation. This enzyme plays an important role in number of diseases including myocardial infarction, congestive heart failure, stroke, neurodegeneration, inflammatory disease, respiratory diseases, retinopathy and others. Speak directly to the analyst to clarify any post sales queries you may have.
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 4 molecules. Out of which approximately 4 molecules are developed by Companies.The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn and Phase I stages are 2, 1 and 1 respectively. Report covers products from therapy areas Hematological Disorders and Toxicology which include indications Anemia in Chronic Kidney Disease (Renal Anemia), Anemia and Chemotherapy Induced Anemia.
The latest report Transmembrane Prolyl 4 Hydroxylase - Drugs In Development, 2022, outlays comprehensive information on the Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)
- The report reviews Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- REPORT COVERAGE
- Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Overview
- Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Companies Involved in Therapeutics Development
- FibroGen Inc
- GSK plc
- Japan Tobacco Inc
- Jiangsu Hengrui Medicine Co Ltd
- Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Drug Profiles
- daprodustat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DDO-3055 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- enarodustat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- molidustat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- roxadustat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Dormant Products
- Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Discontinued Products
- Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Product Development Milestones
- Featured News & Press Releases
- Jun 06, 2022: A roxadustat resurrection: Astellas pull ahead with updated safety data
- May 19, 2022: Astellas analysis shows no evidence of increased risk of cardiovascular events or mortality with Roxadustat compared with erythropoiesis-stimulating agents (ESAs) at 59th ERA Congress 2022
- May 16, 2022: Astellas to present new research further supporting Roxadustat safety in the treatment of symptomatic anemia of chronic kidney disease at 59th ERA Congress 2022
- Apr 25, 2022: Spherix uncovers key differences in the management of chronic kidney disease patients in Europe versus the U.S.
- Apr 19, 2022: US Food and Drug Administration accepts New Drug Application for daprodustat
- Mar 01, 2022: European Medicines Agency (EMA) accepts marketing authorisation application for daprodustat
- Jan 04, 2022: Shenzhen Xinlitai Pharmaceutical announces acceptance of the listing application of Ennarestat Tablets
- Nov 05, 2021: GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease
- Oct 25, 2021: FibroGen announces analyses from roxadustat global phase 3 program at American Society of Nephrology Kidney Week 2021
- Oct 18, 2021: GSK to present update on Daprodustat at the American Society of Nephrology Kidney Week 2021
- Aug 25, 2021: FibroGen announces positive topline results from phase 2 clinical trial of roxadustat for the treatment of chemotherapy induced anemia
- Aug 20, 2021: Astellas receives European Commission approval for first-in-class EVRENZO (roxadustat) for adult patients with symptomatic anemia of chronic kidney disease
- Aug 12, 2021: FDA declines to approve FibroGen’s roxadustat for anaemia of CKD
- Aug 06, 2021: Trials reveal efficacy and safety of oral drug for treating anemia associated with kidney disease
- Jul 19, 2021: GSK’s daprodustat shows positive data for anaemia in Phase III ASCEND trials
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by FibroGen Inc, 2022
- Pipeline by GSK plc, 2022
- Pipeline by Japan Tobacco Inc, 2022
- Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- FibroGen Inc
- GSK plc
- Japan Tobacco Inc
- Jiangsu Hengrui Medicine Co Ltd
